0.40
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ocumetics Technology
Its shares trade on TSX Venture under the ticker OTC.V. It has been listed since 29 August 2018.
Ocumetics Technology Corp. engages in the development of bio lens to completely eliminate the need for corrective lenses, especially for people over 45 years of age. The company is headquartered in Calgary, Alberta. The company went IPO on 2018-08-29. The firm specializes in adaptive lens designs. The firm is focused on developing intraocular lens for people over 45 years of age. The company is in the preclinical study stage of a technology for the ophthalmic industry. The Bionic Lens, which is an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the need for corrective lenses. The company is designed to allow the eye’s natural muscle activity to shift focus from distance to nearby. The Lens consists of self-adapting suspension systems that modulate curvature change. The Lens’s suspension systems are comprised of cushions that are designed to conform to unique parameters of each recipient’s eye. When ciliary muscles relax, during sleep or when the eye focuses upon distant objects, the optical interface is compressed into its high energy state by expansion of the suspension system.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 29 Aug 2018
- Website
- ocumetics.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Calgary, Alberta, with a focus on adaptive lens designs for ophthalmic applications.
- Developing the Bionic Lens, an expandable intraocular lens designed to eliminate the need for corrective lenses for people over 45.
- The company is in the preclinical study stage for its ophthalmic technology, indicating early-stage development.
Weaknesses
- The company is in the preclinical study stage, indicating limited commercial readiness.
- The technology is focused on a specific demographic (people over 45), potentially limiting market size.
- No mention of revenue or financial performance, suggesting early-stage financial challenges.
Opportunities
- Potential market for intraocular lenses in the ophthalmic industry targeting aging populations.
- Adaptive lens technology could address unmet needs in vision correction for older adults.
- Preclinical stage allows for further development and refinement before commercialization.
Threats
- Competition from established ophthalmic technology companies in the market.
- Regulatory hurdles in bringing a new intraocular lens to market.
- Dependence on successful clinical trials to advance from preclinical to clinical stages.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.